Fc fragment of IgG binding protein is correlated with immune infiltration levels in hepatocellular carcinoma

The Fc fragment of IgG binding protein (FCGBP) has been confirmed to play an important role in various cancers. However, the specific role of FCGBP in hepatocellular carcinoma (HCC) remains undefined. Thus, in this study, the enrichment analyses (Gene Ontology [GO], Kyoto Encyclopedia of Genes and Genomes [KEGG], and Gene Set Enrichment Analysis [GSEA]) of FCGBP in HCC and extensive bioinformatic analyses using data of clinicopathologic characteristics, genetic expression and alterations, and immune cell infiltration were perfomed. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to verify the expression of FCGBP in both HCC tissues and cell lines. The subsequent results confirmed that FCGBP overexpression positively correlated with poor prognosis in patients with HCC. Additionally, FCGBP expression could effectively distinguish tumor tissues from normal tissues, which was verified by qRT-PCR. The result was further confirmed by using HCC cell lines. The time-dependent survival receiver operator characteristic curve exhibited the strong ability of FCGBP to predict survival in patients with HCC. Additionally, we revealed the strong relationship between FCGBP expression and a number of classic regulatory targets and classical oncogenic signaling pathways of tumors. Finally, FCGBP was involved in the regulation of immune infiltration in HCC. Therefore, FCGBP has potential value in the diagnosis, treatment, and prognosis of HCC and may be a potential biomarker or therapeutic target.

[1]  F. Shi,et al.  C5aR1 shapes a non-inflammatory tumor microenvironment and mediates immune evasion in gastric cancer , 2022, Bosnian journal of basic medical sciences.

[2]  Bo Wen,et al.  Molecular profiling of core immune-escape genes highlights LCK as an immune-related prognostic biomarker in melanoma , 2022, Frontiers in Immunology.

[3]  Y. Liu,et al.  Complement C1QC as a potential prognostic marker and therapeutic target in colon carcinoma based on single-cell RNA sequencing and immunohistochemical analysis , 2022, Bosnian journal of basic medical sciences.

[4]  Y. Shiue,et al.  Multi-Omics Analyses to Identify FCGBP as a Potential Predictor in Head and Neck Squamous Cell Carcinoma , 2022, Diagnostics.

[5]  Jian Peng,et al.  M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma , 2022, Molecular cancer.

[6]  G. Giamas,et al.  Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients , 2022, Biomedicines.

[7]  V. Mazzaferro,et al.  Immunotherapies for hepatocellular carcinoma , 2021, Nature Reviews Clinical Oncology.

[8]  Lei Yang,et al.  Low expression of TFF3 in papillary thyroid carcinoma may correlate with poor prognosis but high immune cell infiltration. , 2021, Future oncology.

[9]  M. Hsiao,et al.  A Transcriptomic Analysis of Head and Neck Squamous Cell Carcinomas for Prognostic Indications , 2021, Journal of personalized medicine.

[10]  Xiaoming Hu,et al.  Transformable vesicles for cancer immunotherapy. , 2021, Advanced drug delivery reviews.

[11]  Yin Yuan,et al.  H2A.Z acetylation by lincZNF337-AS1 via KAT5 implicated in the transcriptional misregulation in cancer signaling pathway in hepatocellular carcinoma , 2021, Cell Death & Disease.

[12]  Xiaoying Lin,et al.  Prognostic and immunological roles of Fc fragment of IgG binding protein in colorectal cancer , 2021, Oncology letters.

[13]  Bin Yu,et al.  Multidimensional study of CDCA family members in gastric carcinoma with prognostic value , 2021, Bosnian Journal of Basic Medical Sciences.

[14]  T. Ma,et al.  GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy , 2021, Frontiers in Oncology.

[15]  Chao Tan,et al.  Integrated profiling identifies ITGB3BP as prognostic biomarker for hepatocellular carcinoma , 2021, Bosnian journal of basic medical sciences.

[16]  C. Cho,et al.  Identification of cluster of differentiation molecule-associated microRNAs as potential therapeutic targets for gastrointestinal cancer immunotherapy , 2021, The International journal of biological markers.

[17]  C. Cho,et al.  Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons , 2021, Frontiers in Immunology.

[18]  L. Xia,et al.  A bioinformatic analysis: the overexpression and clinical significance of FCGBP in ovarian cancer , 2021, Aging.

[19]  P. Nahon,et al.  Epidemiological projections of viral‐induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[20]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[21]  Xinyu Li,et al.  Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer , 2020, Frontiers in Immunology.

[22]  C. Cho,et al.  Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review , 2020 .

[23]  Salil S. Bhate,et al.  Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front , 2020, Cell.

[24]  Guiyu Wang,et al.  IgG Fc Binding Protein (FCGBP) is Down-Regulated in Metastatic Lesions and Predicts Survival in Metastatic Colorectal Cancer Patients , 2020, OncoTargets and therapy.

[25]  J. Bosch-Barrera,et al.  Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. , 2020, Cancer treatment reviews.

[26]  W. Hoffmann Trefoil Factor Family (TFF) Peptides and Their Diverse Molecular Functions in Mucus Barrier Protection and More: Changing the Paradigm , 2020, International journal of molecular sciences.

[27]  H. Schlüter,et al.  The Tumor Suppressor TFF1 Occurs in Different Forms and Interacts with Multiple Partners in the Human Gastric Mucus Barrier: Indications for Diverse Protective Functions , 2020, International journal of molecular sciences.

[28]  P. Lampertico,et al.  Epidemiology and surveillance for hepatocellular carcinoma: New trends. , 2020, Journal of hepatology.

[29]  A. Satyanarayana,et al.  Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma , 2020, Cancers.

[30]  P. Galle,et al.  Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. , 2020, Journal of hepatology.

[31]  P. Ji,et al.  Application of the microRNA‐302/367 cluster in cancer therapy , 2020, Cancer science.

[32]  Yingyong Hou,et al.  Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors , 2020, Oncoimmunology.

[33]  Yang Wu,et al.  The somatic mutation landscape of Chinese Colorectal Cancer , 2020, Journal of Cancer.

[34]  Salil S. Bhate,et al.  Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front , 2019, Cell.

[35]  R. Russell,et al.  Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm , 2019, Oncogene.

[36]  Kai Zhang,et al.  Integrating proteomics and transcriptomics for the identification of potential targets in early colorectal cancer , 2019, International journal of oncology.

[37]  E. Furth,et al.  Promotion of growth factor signaling as a critical function of β-catenin during HCC progression , 2019, Nature Communications.

[38]  W. Guo,et al.  CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis , 2019, Journal of Hematology & Oncology.

[39]  Y. Mao,et al.  A risk score model for the prediction of osteosarcoma metastasis , 2019, FEBS open bio.

[40]  Dong Chen,et al.  EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation , 2018, Cancer communications.

[41]  R. Weinberg,et al.  Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.

[42]  L. Qin,et al.  C‐C chemokine receptor type 1 mediates osteopontin‐promoted metastasis in hepatocellular carcinoma , 2018, Cancer science.

[43]  Jianping Chen,et al.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer , 2016, Oncoimmunology.

[44]  S. Kaneko,et al.  Molecular Biology of Liver Cancer Stem Cells , 2014, Liver Cancer.

[45]  X. Miao,et al.  NT5E and FcGBP as key regulators of TGF-1-induced epithelial–mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer , 2013, Cell and Tissue Research.

[46]  Miran Kim,et al.  Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. , 2013, Journal of hepatology.

[47]  D. Bae,et al.  Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival , 2012, British Journal of Cancer.

[48]  H. Ogata,et al.  Distribution and partial characterisation of IgG Fc binding protein in various mucin producing cells and body fluids , 2002, Gut.

[49]  A. Oshima,et al.  Human IgGFc Binding Protein (FcγBP) in Colonic Epithelial Cells Exhibits Mucin-like Structure* , 1997, The Journal of Biological Chemistry.

[50]  J. Cheville,et al.  Downregulation of IgG Fc binding protein (Fc gammaBP) in prostate cancer. , 2008, Cancer biology & therapy.